Stay updated on Nivolumab Ipilimumab in CKS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab in CKS Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab in CKS Clinical Trial page
- Check4 days agoChange DetectedThe page update appears to be a cosmetic/layout change with no alteration to core study information (title, eligibility criteria, interventions, outcomes, contacts, or locations). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedCore content updated with a government-operating-status notice and a version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference6%

- Check39 days agoChange DetectedCore page content remains the same; added contact details (phone numbers and email) and updated version to v3.1.0. Removed version v3.0.2.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location in Petah Tikva, Israel, while removing various medical terms and references related to neoplasms and infections.SummaryDifference7%

Stay in the know with updates to Nivolumab Ipilimumab in CKS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab in CKS Clinical Trial page.